Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

Study Summary

Participants are invited to take part in this study because they have AGHD (only severe case). The purpose of this study is to assess long term safety and effectiveness of Sogroya® in patients with AGHD (only severe case) under normal clinical practice condition in Japan. Participants will get Sogroya® as prescribed by the study doctor. Participants will be in the study for about 2 to 5 years depending on when they take part in the study. Participants will be asked to fill in the quality of life questionnaires.

Conditions

Adult Growth Hormone Deficiency

Interventions / Drugs

Somapacitan

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment200 participants

Primary Completion—

Lead SponsorNovo Nordisk A/S

Data Retrieved2026-04-11 02:55:47.366745+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.